Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
复制标题
DOI：
10.1038/s41591-020-0949-6
复制
发表时间：
2020-06-05
期刊：
影响因子：
82.9
通讯作者：
Hou, Fan Fan
中科院分区：
文献类型：
--
作者：
Xu, Xin;Sun, Jian;Hou, Fan Fan
检测无症状或亚临床的新型人类冠状病毒SARS-CoV-2感染对于了解COVID-19的总体患病率和感染潜力至关重要。为估计SARS-CoV-2感染在中国的累积患病率，我们评估了2020年3月9日至2020年4月10日期间，中国武汉市（COVID-19大流行的震中）和中国各地理区域17，368名个体的宿主血清学应答（通过免疫球蛋白M和G水平测量）。在我们的队列中，武汉不同亚队列的血清阳性率在3.2%和3.8%之间变化。随着距离震中的增加，其他城市的血清阳性率逐渐下降。去医院接受维持性血液透析的患者和医护人员的血清阳性率也较高，分别为3.3%（51/1，542，2.5- 4.3%，95%置信区间（CI））和1.8%（81/4，384，1.5- 2.3%，95% CI）。需要更多的研究来确定这些结果是否可推广到其他人群和地理位置，以及确定随着COVID-19大流行的进展，血清阳性率的增长速度。血清学监测可以提供更可靠的SARS冠状病毒感染第一季的累积病毒攻击率，为估计SARS冠状病毒感染在一般人群中的累积患病率提供了有价值的数据。
Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.Initial results of serological surveillance in China provide valuable data for estimation of the cumulative prevalence of SARS-CoV-2 infection in the general population.